Odylia Therapeutics & Foundation Fighting Blindness Webinar Series (#2)

Webinar #2: Disease relevant translation models in ocular drug development: Types, challenges, advantages, and alternatives
Every potential retinal disease therapy, whether small molecule, cell therapy, or genetic technology, will require significant assay development and disease model testing before being considered for clinical use. Over the past half century, the life sciences have seen a technological explosion that enables the research community to model and manipulate biological systems, which has created an expansive tool kit for preclinical development. However, the selection of the right tool for your technology and disease indication can be difficult at times, and if not planned out correctly, can lead to program delays.
This deep-dive webinar highlighted the advantages and disadvantages of certain retinal disease models, and their utility as tools to move new therapies toward Investigational New Drug (IND) filing and clinical use.
Presenters:
Neena Haider, Associate Professor, Harvard University
Kaylan Dulla, Senior Director Ophthalmology Non-Clinical Research, ProQR Therapeutics
Gustavo Aguirre is Professor of Medical Genetics and Ophthalmology at The School of Veterinary Medicine, University of Pennsylvania